FDA gets new power to fast-track drugs from prescription to over-the-counter

What it does

This bill reauthorizes and modifies the FDA's user-fee program for over-the-counter (OTC) monograph drugs—common remedies like antacids and cough syrups that don't require individual drug approval. The bill extends the fee program through 2030, adjusts how much manufacturers must pay based on inflation and workload, and adds new FDA reporting requirements on drug safety and supply-chain stability. It also creates a clearer pathway for prescription drugs to be switched to OTC status and directs the FDA to consider alternatives to animal testing for topical drugs like sunscreens.

Why we flagged it

The bill's core function is reauthorizing an existing FDA fee program for OTC drugs through 2030, with amendments to fee structure, reporting, and regulatory standards. The Rx-to-OTC and animal-testing provisions are substantive modernizations, not riders.

What the text implies

• Voluntary consensus standards for topical-drug testing (Section 6) may allow manufacturers to avoid more rigorous FDA-mandated testing if industry standards are weaker, potentially reducing safety oversight for sunscreens and other topical OTC drugs.
• Fee increases (base revenue plus inflation adjustments) will likely be passed to consumers through higher OTC drug prices, disproportionately affecting lower-income households that rely on affordable OTC remedies.
• The Rx-to-OTC switch pathway (Section 7) accelerates drug reclassification with less prescriptive FDA guidance, potentially enabling faster market access for drugs with limited real-world safety data in OTC settings.
• GAO supply-chain report (Section 5) may reveal FDA gaps in monitoring OTC drug manufacturing, but the bill provides no new enforcement authority to address identified vulnerabilities.
• Sunset clause (October 1, 2030) creates a reauthorization cliff; if Congress fails to act, the entire OTC monograph fee program expires, potentially disrupting FDA oversight of thousands of common drugs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens benefit from enhanced FDA oversight of OTC drugs, clearer pathways for beneficial Rx-to-OTC switches, and reduced animal testing. However, manufacturer fees may be passed to consumers through higher OTC drug prices, and the bill's reliance on voluntary industry standards for testing (rather than mandatory FDA-set standards) may weaken safety assurance for topical products.

Who stands to gain

• OTC drug manufacturers (reduced regulatory burden via voluntary standards and streamlined Rx-to-OTC
• Contract manufacturing organizations (registration and fee collection framework)
• Pharmaceutical companies seeking Rx-to-OTC switches (clearer approval pathway, reduced animal testin

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), OTC monograph drug manufacturers, Contract manufacturing organizations, Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce, GAO (Government Accountability Office), Voluntary consensus standards development organizations

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Jul 15, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jul 15, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Jul 30, 2025 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 8 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,825,234 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

Jim Banks, the sponsor, reported $559,626 in PAC receipts in the 2026 cycle.

• American Academy of Dermatology Association — $1,030,000 on 2 filings
• Consumer Healthcare Products Association — $445,234 on 2 filings
• Haleon Us Holdings LLC — $210,000 on 1 filing
• Chattem, Inc. Dba Opella — $60,000 on 1 filing
• Haleon Us Holdings LLC — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.